NATODefenceNATO elevates biotech to defence priorityThe NATO is clearly priorising biotech to a defence priority with an annual budget of potentially up to €500m for biotech start-ups starting from 2026. At the opening of the first ever NATO Biotechnology … more ➔
GSKLicence dealGSK licences siRNA COPD drug in US$745m biobucks dealBritish GlaxoSmithKline plc (GSK) has entered a US$745m licensing agreement with Empirico Inc for EMP-012, a first-in-class siRNA candidate for COPD. EMP-012 targets the underserved non-type 2 inflammation … more ➔
adobe stock photos - Michael Derrer Fuchs M&ANovartis acquires Avidity Biosciences for US$12bnIn a major bet on RNA medicine, Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity’s Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA delivery … more ➔
Adobe stock photo - tippapatt FinancingGHO Capital expands healthcare reach with €2.5bn Fund IV closeGHO Capital has closed its fourth fund, GHO Capital IV LP, raising over €2.5bn (~US$2.9bn) to invest in global healthcare. The fund brings the firm’s total assets under management to around €9bn, … more ➔
adobe stock photos - Jiraporn FinancingHemab Therapeutics bags US$157m in Series C financingHemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatment … more ➔
IPCEI Med4CureIndustrial BiotechSynbio alliance strengthens EU corticosteroid supply chainThe French AI-synbio specialist Abolis Biotechnologies SAS has entered a strategic €140m alliance with API manufacturer EuroAPI SA under the IPCEI Med4Cure funding programme. Within the collaboration, … more ➔
adobe stock photos - Miha Creative Financing/PartneringVC investments rise nearly 71% in Q3 2025VC investments in biotech rose 70.9% in Q3 2025 to US$3.1bn, driven by Series D growth, M&A activity, and Fed interest rate cuts, reports Global Data. J.P. Morgan reports same trends but different f … more ➔
Pleiotrope - https://commons.wikimedia.org/w/index.php?curid=15999847Financing/PartneringElectra Therapeutics raises US$183m in Series C financingCalifornia-based biotech Electra Therapeutics Inc has secured US$183m in Series C financing. The investment comes from a consortium of four European investors and Mubadala Capital. Contrary to some … more ➔
Ipsen SAM&AIpsen acquires ImCheck in US$1bn dealPharma giant Ipsen will pay US$1bn to acquire French immuno-oncology firm ImCheck Therapeutics SAS. The deal includes US$350m upfront and up to US$650m in milestone payments. ImCheck focuses on butyrophilins, … more ➔
BIOCOM InterrelationsESMO 2025Tubulis presents first clinical data on ADC TUB-040Following its US$361 m Series C financing, Tubulis AG presented first Phase I/IIa data on its lead ADC, TUB-040, at ESMO 2025 in Berlin. The study focuseds on patients with platinum-resistant ovarian … more ➔
NATO
GSK
adobe stock photos - Michael Derrer Fuchs 
Adobe stock photo - tippapatt 
adobe stock photos - Jiraporn 
IPCEI Med4Cure
adobe stock photos - Miha Creative 
Pleiotrope - https://commons.wikimedia.org/w/index.php?curid=15999847
Ipsen SA
BIOCOM Interrelations